** Citi finds improved sales momentum and positive operating cash flow in Bubs Australia's BUB.AX trading update
** Brokerage lifts price target to A$0.14 from A$0.13, maintains "neutral/high risk" rating
** Infant formula maker reported 1H25 EBITDA of A$2.9 mln ($1.82 mln) vs EBITDA loss of A$6.8 mln in the same period last year
** Citi sees co's FY25 rev guidance of A$102 mln to be achievable
** Brokerage, however, flags uncertainty around U.S. FDA approval and sustained positive cash flow as risks
** Stock up 20% so far this year as of last close
($1 = 1.5946 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.